Skip to main content
Sign In

School of Medicine Departments

Ross Kedl, Ph.D.

Associate Professor of Immunology & Microbiology

   Phone: TBD

The activation of adaptive immune responses is critically dependent upon the activation of innate immune cells and mediators.  However, the precise innate signals and pathways that best negotiate the transition from innate to adaptive have yet to be elucidated.  A number of years of work have made it clear that the stimulation of innate pathways is alone insufficient for the eventual production of adaptive cellular immunity.  Mere stimulation of the one or more innate receptors does not recapitulate the bulk of the infectious process that leads to potent adaptive immunity.  Collectively the field has arrived at the conclusion that inflammation alone is a necessary, but insufficient, component of the eventual production of cellular immunity.  

Our lab is interested in this curious boundary between the innate and adaptive immune systems and seeks to elucidate signals and pathways emanating from the various families of innate receptors most efficiently mediate the transition to the adaptive cellular immune response.  In doing so, we seek to determine not only the basic rules of immunity, many of which remain elusive, but also to identify practical methods of intervention for the purposes of vaccine discovery, development and design.  Experimentally we have demonstrated a number of ways in which the innate pathways intersect with the TNF receptor/Ligand superfamily, resulting in potent T cell expansion, effector function, and memory generation.  These discoveries and novel vaccination methods are being applied to both viral and tumor model systems in an effort to develop clinically relevant methods of therapeutic vaccination against diseases such as chronic infections and cancer.

Dr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Under construction

Lab Protocols (PDF documents)

Mouse strains we have:


​CD70 KO Founders Germline Pup!!​
 Formal Strain Name Informal Strain Name Phenotype
 C57BL/6J  B6  Control
   B6/129 F1  Control
 B6SJLF-PtprcaPep3b/BoyJ  B6.SJL  Control
 B6Cr.129S4-Tnfsf7tm1Sug/Pgn  CD27 KO  CD27 deficient
 B6129PF2/ifnab  IFNaR KO  IFN receptor deficient
 129S6/SvEv-Stat1tm1Rds  STAT1 KO  STAT1 deficient
 129S6/SvEv-Stat4tm1Rds  STAT4 KO  STAT4 deficient
 B6Cr.129S4-Tnfsf4tm1Sug/Pgn  OX40 KO  OX40 deficient
 B6.129S2-H2dlAb1-Ea/J  Class II KO  Class Ii deficient
 B6.DTR-CD11c  CD11c DTR  conditional deletion of CD11c+ cells upon DT administration
 B6.DTR-FoxP3-GFP  DTR FoxP3  conditional deletion of FoxP3+ cells upon DT administration
 B6.FVB-Tg(Itgax-DTR/EGFP)57Lan/J  Lang DTR  conditional deletion of langerhans cells upon DT administration
 B6.FVB-Tg(Itgax-DTA/EGFP)Lan/J  Lang DTA  langerhans cell deletion
 C.129S1-Il12rb1tm1Jm/J  IL-12Rb1 KO  IL-12Rb1 deficient
 C.129S1-Il12rb2tm1Jm/J  IL-12Rb2 KO  IL-12Rb2 deficient
 C.129S1-Il23p19tm1Jm/J  IL-23p19 KO  IL23p19 deficient
 C.129S1-Il27rtm1Jm/J  IL-27R KO  IL-12 receptor deficient
 B6.129P2-Cd40tm1Kik/J  TRAF5 KO  TRAF5 deficient
 C57BL/6-Tg(TcraTcrb)1100MjB/J  OT1  ova specific TCR transgenic
   gB-T1  HSV gB-specific TCR transgenic
 B6;D2-Tg(TcrLCMV)327Sdz/JDvsJ  P14  LCMV GP TCR transgenic
 C57BL/6-Tg(TcraTcrb)425Cbn/J  OTII  ova specific CD4+ TCR transgenic
 B6.129P2(Cg)-MyD88tm1.1Defr/J  MyD88 KO  MyD88 deficient
 B6.129S1-Tlr7tm1Flv/J  TLR7 KO  TLR7 deficient
 B6;129S1-Tlr3tm1Flv/J  TLR3 KO  TLR3 deficient
 C57BL/6NTac-IL15tm1Imx  IL-15Ra KO  IL15R alpha deficient
 B6.129s4-il2rbtm1Dw/J  CD122 KO  CD122 deficient
 Prdm1gfp/gfp  Blimp-1-YFP  Blimp-1 expression of YFP
 129SvEvBatF3-/-  BatF3 KO  BatF3 transcription factor deficient
 B6;129P2-Rag1/Rag2tm1Mnz/J  Rag2 KO  Rag2 deficient
 B6.129p2-CD40<tm1Kik>/J  CD40 KO  CD40 deficient
 B6-Tnflsf7tm1  CD70 KO  CD70 deficient